Tuesday, April 07, 2015 8:37:32 PM
Plus no mention of the product that is 1-2 years out for osteoarthritis of the knee.
Article claims CBMG evaluation was based on Car-t product which they purchased for 1.8 million, when in reality majority of the company's evaluation is based on the progress of the osteoarthritis product.
It is going to be interesting to see how company responds in am, and how bad the final fall out will be.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM